Patent US4877611A successfully refreshed from Google Patents.
US4877611A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Vaccine containing tumor antigens and adjuvants
Assignee: Ribi Immunochem Research Inc
•
Filing: 1987-09-30
•
Granted: 1989-10-31
•
Expires: 2007-09-30
Abstract
Abstract Vaccines are provided which are composed of (a) non-toxic and highly effective adjuvants obtained from microbial sources, together with (b) tumor antigens. A wide variety of antigens can be employed in the vaccines and include, antigens obtained from tumors or cultures of tumor cells, such as ovarian cancers, melanomas, colorectal cancers, pancreatic cancers, renal cancers and the like. By adding tumor antigens to potent but non-toxic immunostimulants, a protective and lasting tumor immunity can be obtained.
Inventors
- 👤 John L. Cantrell
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 13:41
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/39; A61K39/0005; A61K39/0011; A61K2039/555; A61K2039/55511; A61K2039/55544; A61K2039/5555; A61K2039/55566; A61K2039/55588; A61K2039/55594
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
64 words
A vaccine useful for the treatment and prevention of tumors in a host, said vaccine comprised of: (a) at least one tumor-associated antigen, (b) a refined detoxified endotoxin immunostimulant, and (c) at least one biological immunostimulant selected from the group consisting of: (1) mycobacterial cell wall skeleton (2) trehalose dimycolate, and (3) pyridine soluble extract of a microorganism, and (d) a pharmaceutically acceptable carrier.
Claim 2
Dependent Claim
64 words
A vaccine useful for the treatment and prevention of tumors in a host, said vaccine comprised of: (a) at least one tumor-associated antigen, (b) a refined detoxified endotoxin immunostimulant, and (c) at least one biological immunostimulant selected from the group consisting of: (1) mycobacterial cell wall skeleton (2) trehalose dimycolate, and (3) pyridine soluble extract of a microorganism, and (d) a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim
32 words
The vaccine of claim 1 wherein said refined detoxified endotoxin has no detectable 2-keto-3-deoxyoctonoate between about 350 and 475 nmoles/mg of phosphorus and between about 1700 and 2000 nmoles/mg of fatty acids.
Claim 4
Dependent Claim
14 words
The vaccine of claim 1 wherein said refined detoxified endotoxin is monophosphoryl lipid A.
Claim 5
Dependent Claim
13 words
The vaccine of claim 1 wherein component (c) is mycobacterial cell wall skeleton.
Claim 6
Dependent Claim
11 words
The vaccine of claim 1 wherein component (c) is trehalose dimycolate.
Claim 7
Dependent Claim
16 words
The vaccine of claim 1 wherein component (c) is a pyridine soluble extract of a microorganism.
Claim 8
Dependent Claim
19 words
The vaccine of claim 1 wherein component (c) is a combination of mycobacterial cell wall skeleton and trehalose dimycolate.
Claim 9
Dependent Claim
24 words
The vaccine of claim 1 wherein component (c) is a combination of mycobacterial cell wall skeleton and a pyridine soluble extract of a microorganism.
Claim 10
Dependent Claim
22 words
The vaccine of claim 1 wherein component (c) is a combination of trehalose dimycolate and a pyridine soluble extract of a microorganism.
Claim 11
Dependent Claim
26 words
The vaccine of claim 1 wherein component (c) is a combination of mycobacterial cell wall skeleton, trehalose dimycolate and a pyridine soluble extract of a microorganism.
Claim 12
Dependent Claim
43 words
The vaccine of claim 1 wherein said pyridine soluble extract from said microorganism contains between about 7 and 20% by weight of protein, between about 10 and 16% by weight of sugar, and between about 35 and 55% by weight of fatty acids.
Claim 13
Dependent Claim
71 words
A process for the preparation fo a vaccine useful for the treatment and prevention of tumors in a host which comprises forming a mixture of: (a) at least one tumor associated antigen (b) a refined detoxified endotoxin (c) at least one biological immunostimulant selected from the group consisting of: (1) mycobacterial cell wall skeleton (2) trehalose dimycolate, and (3) pyridine soluble extract of a microorganism, and (d) a pharmaceutically acceptable carrier
Claim 14
Dependent Claim
71 words
A process for the preparation fo a vaccine useful for the treatment and prevention of tumors in a host which comprises forming a mixture of: (a) at least one tumor associated antigen (b) a refined detoxified endotoxin (c) at least one biological immunostimulant selected from the group consisting of: (1) mycobacterial cell wall skeleton (2) trehalose dimycolate, and (3) pyridine soluble extract of a microorganism, and (d) a pharmaceutically acceptable carrier
Claim 15
Dependent Claim
74 words
A process for the treatment and prevention of tumors in a host, which comprises administering to said host an anti-tumor effective amount of a vaccine comprised of: (a) at least one tumor associated antigen, (b) a refined detoxified endotoxin immunostimulant, and (c) at least one biological immunostimulant from the group consisting of: (1) mycobacterial cell wall skeleton, (2) trehalose dimycolate, and (3) pyridine soluble extract of a microorganism, and (d) a pharmaceutically acceptable carrier.
Claim 16
Dependent Claim
74 words
A process for the treatment and prevention of tumors in a host, which comprises administering to said host an anti-tumor effective amount of a vaccine comprised of: (a) at least one tumor associated antigen, (b) a refined detoxified endotoxin immunostimulant, and (c) at least one biological immunostimulant from the group consisting of: (1) mycobacterial cell wall skeleton, (2) trehalose dimycolate, and (3) pyridine soluble extract of a microorganism, and (d) a pharmaceutically acceptable carrier.
Claim 17
Dependent Claim
32 words
The process of claim 13 wherein said refined detoxified endotoxin has no detectable 2-keto-3-deoxyoctonoate, between about 350 and 475 nmoles/mg of phosphorus and between about 1700 and 2000 nmoles/mg of fatty acids.
Claim 18
Dependent Claim
14 words
The process of claim 13 wherein said refined detoxified endotoxin is monophosphoryl lipid A.
Claim 19
Dependent Claim
13 words
The process of claim 13 wherein component (c) is mycobacterial cell wall skeleton.
Claim 20
Dependent Claim
11 words
The process of claim 13 wherein component (c) is trehalose dimycolate.
Claim 21
Dependent Claim
16 words
The process of claim 13 wherein component (c) is a pyridine soluble extract of a microorganism.
Claim 22
Dependent Claim
19 words
The process of claim 13 wherein component (c) is a combination of mycobacterial cell wall skeleton and trehalose dimycolate.
Claim 23
Dependent Claim
23 words
The process of claim 13 wherein component (c) is a combination of mycobacterial cell wall skeleton and a pyridine extract of a microorganism.
Claim 24
Dependent Claim
22 words
The process of claim 13 wherein component (c) is a combination of trehalose dimycolate and a pyridine soluble extract of a microorganism.
Claim 25
Dependent Claim
26 words
The process of claim 13 wherein component (c) is a combination of mycobacterial cell wall skeleton, trehalose dimycolate and a pyridine soluble extract of a microorganism.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-10-30 | 1993-05-01 | 1993-10-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-10-30 | 1997-05-01 | 1997-10-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-10-30 | 2001-05-01 | 2001-10-31 | $7700.00 | Window Closed / Lapsed |